Clinical Trial Update: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating the combination of Patritumab Deruxtecan (HER3-DXd) with Osimertinib in patients with locally advanced or metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Patritumab Deruxtecan (patritumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Status: ACTIVE_NOT_RECRUITING